Accès gratuit
Numéro
Therapie
Volume 68, Numéro 4, Juillet-Août 2013
XXVIIIes Rencontres Nationales de Pharmacologie et Recherche Clinique, Innovation et Évaluation des Technologies de Santé, Tables rondes GIENS – 7 au 9 octobre 2012
Page(s) 247 - 252
DOI https://doi.org/10.2515/therapie/2013038
Publié en ligne 28 août 2013
  1. Le Gales C, el Hasnaoui A, Goehrs JM. Postmarketing evaluation of drugs. Actual efficacy, population exposed and impact on public health. Therapie 2003; 58(3): 209-19 [CrossRef] [EDP Sciences] [PubMed]
  2. Vray M, Hamelin B, Jaillon P. The respective roles of controlled clinical trials and cohort monitoring studies in the pre- and postmarketing assessment of drugs. Therapie 2005; 60(4): 339-44, 345-9 [CrossRef] [EDP Sciences] [PubMed]
  3. Tubach F, Lamarque-Garnier V, Castot A. Role of the post-marketing authorisation studies in drug risk surveillance: specifications and methodologies. Therapie 2011; 66(4): 355-62, 347-54 [CrossRef] [EDP Sciences] [PubMed]
  4. Gueyffier F, Strang CB, Berdaux G, et al. Contribution of modeling approaches and virtual populations in transposing the results of clinical trials into real life and in enlightening public health decisions. Therapie 2012; 67(4): 367-74 [CrossRef] [EDP Sciences] [PubMed]
  5. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300 [PubMed]
  6. Haute autorité de santé. Élaboration de recommandations de bonne pratique : Méthode « Recommandations pour la pratique clinique » in Guide méthodologique. 2010. http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-01/guide_methodologique_recommandations_pour_la_pratique_clinique.pdf
  7. Trans Durieux N, Pasleau F, Howick J. Table des niveaux de preuves du Centre d’Evidence‐Based Medicine d’Oxford (OCEBM Levels of Evidence Working Group). The Oxford 2011 Levels of Evidence, 2011. http://www.cebm.net
  8. Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011; 64(4): 401-6 [CrossRef] [PubMed]
  9. Howick J, Glasziou P, Aronson JK. The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute? J R Soc Med 2009; 102(5): 186-94 [CrossRef] [PubMed]
  10. Howick JP, Glasziou P, Aronson JK. Evidence-based mechanistic reasoning. J R Soc Med 2010; 103(11): 433-41 [CrossRef] [PubMed]
  11. Wald NJ, Morris JK. Teleoanalysis: combining data from different types of study. BMJ 2003, 327 (7415): 616-8 [CrossRef] [PubMed]
  12. Loke YK, Price D, Herxheimer A. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol 2007; 7: 32 [CrossRef] [PubMed]
  13. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007; 30(8): 2148-53 [CrossRef] [PubMed]
  14. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356 (9237): 1255-9 [CrossRef] [PubMed]
  15. Blake KV, Devries CS, Arlett P, et al. Increasing scientific standards, independence and transparency in post-authorisation studies: the role of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Pharmacoepidemiol Drug Saf 2012; 21 (7): 690-6 [CrossRef] [PubMed]
  16. Blake KV, Prilla S, Accadebled S, et al. European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Pharmacoepidemiol Drug Saf 2011; 20(10): 1021-9 [CrossRef] [PubMed]
  17. Berger ML, Dreyer L, Anderson F, et al. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report. Value Health 2012; 15(2): 217-30 [CrossRef] [PubMed]
  18. Stamenkovic S, Solesse A, Zanetti L, et al. French Health Authority (HAS) Guidance: the post-registration studies on health technologies (drugs, medical devices and instruments): principles and methods. Therapie 2012; 67(5): 409-21 [CrossRef] [EDP Sciences] [PubMed]